Abstract
Background: Reports of cardiovascular adverse events (AEs) associated with the use of cyclooxygenase-2 inhibitors for the treatment of osteoarthritis (OA) have prompted the quest for a better-tolerated NSAID.
Objective: The aim of this study was to compare the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult Indian patients with OA of the hip or knee.
Methods: This 4-week, double-blind, randomized, comparative, multicenter study was undertaken to compare oral lornoxicam and diclofenac in patients with OA. Patients who met the selection criteria were enrolled consecutively from the outpatient clinics of each of the participating hospitals in India. Participants completed the Western Ontario and McMasters Individual Osteoarthritis Index (WOMAC-OA), WOMAC Composite Index (WOMAC-CI) (for pain, stiffness, and physical function), and a 10-cm visual analog scale (VAS) (0–10 where 0 = no pain and 10 = worst possible pain or severe or excruciating pain) at each study visit (weeks 0 [baseline], 2, and 4 [or at early termination]). Patients' and physicians' global assessments of arthritis control were measured at each study visit when laboratory and clinical AEs were also monitored. The primary end points were the WOMAC-OA, the WOMAC-CI, and VAS scores for pain among the patients who completed the study.
Results: Of the 273 patients (159 men, 114 women; mean [SD] age, 44.73 [10.72] years; range, 28–68 years) enrolled in the study, 13 (7 in the lornoxicam group and 6 in the diclofenac group) were lost to follow-up and their effectiveness and tolerability results were not included in the study analysis. Over the 4-week study period, both drugs provided significant (P < 0.05) sustained relief of OA symptoms compared with baseline. Compared with baseline, the mean pain score (WOMAC-CI) decreased 90.6% (13.88 [4.47] vs 1.30 [1.49]; P < 0.05) in the lornoxicam group and 88.9% (14.15 [4.56] vs 1.57 [1.49]; P < 0.05) in the diclofenac group after 4 weeks of treatment. After 4 weeks of treatment, the VAS pain score decreased from baseline 83.1% (8.04 [2.70] vs 1.36 [1.43]; P < 0.05) in the lornoxicam group and 79.3% (7.98 [2.98] vs 1.65 [1.47]; P < 0.05) in the diclofenac group. Compared with baseline, the improvement rated at 2 weeks was not significantly different between the 2 groups. Lornoxicam and diclofenac were well tolerated. The rate of mild to moderate adverse gastrointestinal events was not significantly different in the lornoxicam group compared with the diclofenac group (14.6% vs 18.4%). Similarly, overall tolerability between the 2 groups was not significantly different. None of the patients experienced cardiovascular AEs (eg, edema or increased blood pressure).
Conclusion: The results of the present study suggest that lornoxicam was comparable to diclofenac in effectiveness and tolerability after 4 weeks of treatment in these adult Indian patients with OA of the hip or knee who completed the study.
Key words: lornoxicam, diclofenac, osteoarthritis, India
Full Text
The Full Text of this article is available as a PDF (920.1 KB).
References
- 1.Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol. 2006;20:117–129. doi: 10.1016/j.berh.2005.09.004. [DOI] [PubMed] [Google Scholar]
- 2.Pruss TO, Stroissing H, Radhofer-Welte S. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990;66(Suppl 4):S18–S21. [PubMed] [Google Scholar]
- 3.Berry H, Bird HA, Black C. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis. 1992;51:238–242. doi: 10.1136/ard.51.2.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Rose P, Steinhauser C. Comparison of lornoxicam and rofecoxib in patients with activated osteoarthritis (COLOR Study) Clin Drug Investig. 2004;24:227–236. doi: 10.2165/00044011-200424040-00004. [DOI] [PubMed] [Google Scholar]
- 5.Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol. 1996;23:1605–1611. [PubMed] [Google Scholar]
- 6.Altman R, Asch E, Bloch D, Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039–1049. doi: 10.1002/art.1780290816. [DOI] [PubMed] [Google Scholar]
- 7.Altman R, Alarcón G, Appelrouth D. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–514. doi: 10.1002/art.1780340502. [DOI] [PubMed] [Google Scholar]
- 8.Balfour JA, Fitton A, Barradell LB. Lornoxicam: A review of its pharmacology and therapeutic potential in the management of painful inflammatory conditions. Drugs. 1996;51:639–657. doi: 10.2165/00003495-199651040-00008. [DOI] [PubMed] [Google Scholar]
- 9.Todd PA, Sorken EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1988;35:244–285. doi: 10.2165/00003495-198835030-00004. [DOI] [PubMed] [Google Scholar]
- 10.Ghosh S, Paul S, Das N, Bhattacharyya TK. A study on the effects of diclofenac sodium and etoricoxib in the treatment of osteoarthritis. J Indian Med Assoc. 2007;105:260–262. [PubMed] [Google Scholar]
- 11.Banning M. The use of topical diclofenac for pain in osteoarthritis of the knee: A review. Br J Community Nurs. 2006;11:487–492. doi: 10.12968/bjcn.2006.11.11.22278. [DOI] [PubMed] [Google Scholar]
- 12.Aabakken L, Osnes M, Frenzel W. Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment Pharmacol Ther. 1996;10:151–156. doi: 10.1046/j.1365-2036.1996.719899000.x. [DOI] [PubMed] [Google Scholar]